Real-World Alcohol Use Disorder Outcomes in Patients With Concurrent Metabolic Dysfunction: GLP-1 Receptor Agonists Versus FDA-Approved AUD Medications - PubMed
14 hours ago
- #Alcohol Use Disorder
- #Metabolic Dysfunction
- #GLP-1RA
- Study compares GLP-1 receptor agonists (GLP-1RAs) with FDA-approved medications for Alcohol Use Disorder (AUD) in patients with concurrent metabolic dysfunction (MetD).
- GLP-1RAs showed lower 1-year AUD relapse rates (IRR 0.55), greater BMI reduction (-1.3 vs. -0.3), and improved HbA1c (-1.0 vs. +0.1) compared to traditional AUD medications.
- Patients on GLP-1RAs had higher baseline BMI (35.5 vs. 30.1) and more type 2 diabetes (66% vs. 14%).
- Trends suggested better liver outcomes with GLP-1RAs, though not statistically significant for decompensated cirrhosis (HR 0.52, p = 0.09).
- Mortality rates were similar between GLP-1RA and traditional AUD medication groups.
- GLP-1RAs are promising for dual-risk patients (MetD and AUD), improving both metabolic and AUD outcomes.